LEVOTHYROXINE SODIUM
| Brand name | ERMEZA |
|---|---|
| Active ingredient | LEVOTHYROXINE SODIUM |
| Strength | 150MCG/5ML |
| Dosage form | SOLUTION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | April 2022 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 9345772 | February 2035 | product |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.